Andrew S Huhn1, J Gregory Hobelmann2, George A Oyler3, Eric C Strain4. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA; Ashley Addiction Treatment, Havre de Grace, MD, 21078, USA. Electronic address: ahuhn1@jhu.edu. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA; Ashley Addiction Treatment, Havre de Grace, MD, 21078, USA. 3. Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA. 4. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.
Abstract
INTRODUCTION: The illicit opioid supply in the U.S. is increasingly adulterated with fentanyl. As such, persons with opioid use disorder (OUD) may be regularly exposed to fentanyl, however, the pharmacokinetics of repeated fentanyl exposure are not well understood. The current study aimed to quantify renal clearance of fentanyl in OUD patients presenting to residential treatment. METHODS: Participants (N = 12) who presented to a 28-day residential treatment program were enrolled if they tested positive for fentanyl at intake. Urine samples were collected every 2-3 days and were quantitatively tested for fentanyl, norfentanyl, and creatinine via liquid chromatography mass spectrometry (LC-MS). Fentanyl clearance was defined as the time since last illicit opioid use and the median time between last positive and first negative fentanyl urine screen. RESULTS: Participants had a mean and standard deviation (SD) age of 28.9 (11.0), were 67 % male, and 83 % white. The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively. One participant continued to test positive for fentanyl for 19 days and norfentanyl for 26 days following their last use, and left treatment without testing negative for norfentanyl. CONCLUSION: Fentanyl clearance in persons with OUD is considerably longer than the typical 2-4 day clearance of other short-acting opioids. The findings of this study might explain recent reports of difficulty in buprenorphine inductions for persons who use fentanyl, and point to a need to better understand the pharmacokinetics of fentanyl in the context of opioid withdrawal in persons who regularly use fentanyl.
INTRODUCTION: The illicit opioid supply in the U.S. is increasingly adulterated with fentanyl. As such, persons with opioid use disorder (OUD) may be regularly exposed to fentanyl, however, the pharmacokinetics of repeated fentanyl exposure are not well understood. The current study aimed to quantify renal clearance of fentanyl in OUD patients presenting to residential treatment. METHODS:Participants (N = 12) who presented to a 28-day residential treatment program were enrolled if they tested positive for fentanyl at intake. Urine samples were collected every 2-3 days and were quantitatively tested for fentanyl, norfentanyl, and creatinine via liquid chromatography mass spectrometry (LC-MS). Fentanyl clearance was defined as the time since last illicit opioid use and the median time between last positive and first negative fentanyl urine screen. RESULTS:Participants had a mean and standard deviation (SD) age of 28.9 (11.0), were 67 % male, and 83 % white. The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively. One participant continued to test positive for fentanyl for 19 days and norfentanyl for 26 days following their last use, and left treatment without testing negative for norfentanyl. CONCLUSION:Fentanyl clearance in persons with OUD is considerably longer than the typical 2-4 day clearance of other short-acting opioids. The findings of this study might explain recent reports of difficulty in buprenorphine inductions for persons who use fentanyl, and point to a need to better understand the pharmacokinetics of fentanyl in the context of opioid withdrawal in persons who regularly use fentanyl.
Authors: Alexandria Macmadu; Jennifer J Carroll; Scott E Hadland; Traci C Green; Brandon D L Marshall Journal: Addict Behav Date: 2017-01-06 Impact factor: 3.913
Authors: Neil B Varshneya; Ashish P Thakrar; J Gregory Hobelmann; Kelly E Dunn; Andrew S Huhn Journal: J Addict Med Date: 2021-11-23 Impact factor: 4.647
Authors: Ryan R Cook; Randy Torralva; Caroline King; Paula J Lum; Hansel Tookes; Canyon Foot; Pamela Vergara-Rodriguez; Allan Rodriguez; Laura Fanucchi; Gregory M Lucas; Elizabeth N Waddell; P Todd Korthuis Journal: Drug Alcohol Depend Date: 2021-09-20 Impact factor: 4.492
Authors: August F Holtyn; Forrest Toegel; Matthew D Novak; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: Drug Alcohol Depend Date: 2021-05-27 Impact factor: 4.852
Authors: Jessica L Taylor; Samantha Johnson; Ricardo Cruz; Jessica R Gray; Davida Schiff; Sarah M Bagley Journal: J Gen Intern Med Date: 2021-06-22 Impact factor: 5.128